Benjamin Burnett
Stock Analyst at Wells Fargo
(3.76)
# 749
Out of 5,113 analysts
92
Total ratings
57.35%
Success rate
7.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Overweight | $157 → $193 | $185.17 | +4.23% | 3 | Jan 13, 2026 | |
| AVDL Avadel Pharmaceuticals | Maintains: Equal-Weight | $20 → $23 | $21.54 | +4.46% | 3 | Nov 20, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Overweight | $30 → $35 | $25.24 | +38.67% | 3 | Nov 13, 2025 | |
| ALKS Alkermes | Maintains: Overweight | $42 → $37 | $33.90 | +9.14% | 3 | Nov 13, 2025 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.21 | +147.93% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $53.69 | -8.74% | 6 | Feb 13, 2025 | |
| ACLX Arcellx | Maintains: Buy | $83 → $122 | $68.14 | +79.04% | 5 | Oct 18, 2024 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $29.02 | +137.77% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $33.65 | +102.08% | 7 | Sep 10, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Hold | $4.4 → $4.6 | $1.45 | +217.24% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $58 | $5.50 | +945.45% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $3.99 | +19,448.87% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $45 | $24.44 | +84.12% | 1 | Dec 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $5.61 | +60.43% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $217 → $234 | $155.89 | +50.11% | 1 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $48 | $41.95 | +14.42% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $29 | $12.73 | +127.81% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $8 | $5.64 | +41.84% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $23 | $17.83 | +29.00% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $73 → $93 | $75.60 | +23.02% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $414 → $423 | $467.30 | -9.48% | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $97.33 | -34.24% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $80.01 | +17.49% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $4 | $2.64 | +51.50% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $4.46 | +124.22% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $2.75 | +809.09% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $35.91 | +902.51% | 2 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $16 | $0.36 | +4,296.81% | 1 | Jan 6, 2021 |
Axsome Therapeutics
Jan 13, 2026
Maintains: Overweight
Price Target: $157 → $193
Current: $185.17
Upside: +4.23%
Avadel Pharmaceuticals
Nov 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $21.54
Upside: +4.46%
Centessa Pharmaceuticals
Nov 13, 2025
Maintains: Overweight
Price Target: $30 → $35
Current: $25.24
Upside: +38.67%
Alkermes
Nov 13, 2025
Maintains: Overweight
Price Target: $42 → $37
Current: $33.90
Upside: +9.14%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.21
Upside: +147.93%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $53.69
Upside: -8.74%
Arcellx
Oct 18, 2024
Maintains: Buy
Price Target: $83 → $122
Current: $68.14
Upside: +79.04%
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $29.02
Upside: +137.77%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $33.65
Upside: +102.08%
Allogene Therapeutics
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $1.45
Upside: +217.24%
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $5.50
Upside: +945.45%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $3.99
Upside: +19,448.87%
Dec 30, 2025
Maintains: Overweight
Price Target: $65 → $45
Current: $24.44
Upside: +84.12%
Dec 18, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $5.61
Upside: +60.43%
Dec 16, 2025
Maintains: Overweight
Price Target: $217 → $234
Current: $155.89
Upside: +50.11%
Dec 11, 2025
Maintains: Overweight
Price Target: $44 → $48
Current: $41.95
Upside: +14.42%
Dec 9, 2025
Maintains: Overweight
Price Target: $16 → $29
Current: $12.73
Upside: +127.81%
Nov 11, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $5.64
Upside: +41.84%
Nov 11, 2025
Maintains: Overweight
Price Target: $26 → $23
Current: $17.83
Upside: +29.00%
Nov 5, 2025
Maintains: Overweight
Price Target: $73 → $93
Current: $75.60
Upside: +23.02%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $414 → $423
Current: $467.30
Upside: -9.48%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $97.33
Upside: -34.24%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $80.01
Upside: +17.49%
Dec 13, 2024
Maintains: Buy
Price Target: $9 → $4
Current: $2.64
Upside: +51.50%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $4.46
Upside: +124.22%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $2.75
Upside: +809.09%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $35.91
Upside: +902.51%
Jan 6, 2021
Initiates: Hold
Price Target: $16
Current: $0.36
Upside: +4,296.81%